Frazier Life Sciences Builds 15.3% Stake in Attovia Therapeutics After IPO, Adding $3.3M in Open Market Buys
ATTO is trading near its 52-week low of $18.5 (0.8% above the low) on light trading volume (0.4× avg).
Summary
Frazier Life Sciences reports a 15.3% stake in Attovia Therapeutics, including $3.3 million in post-IPO open market purchases, reinforcing institutional support as the stock hovers near lows.
Key Events · Ownership and Investor Activity · ATTO
-
Frazier Group Holds 15.3% Stake
Collectively, Frazier Life Sciences entities own 6,968,703 shares, or 15.3% of the outstanding total. FLS XI holds 6,154,213 shares (13.5%), while FLSPF holds 760,327 shares (1.7%).
-
$3.3M in Post-IPO Open Market Buys
On August 5–7, FLSPF and FLS XII purchased $3,306,368.83 worth of shares at prices ranging from $19.37 to $22.00, adding to the $10 million IPO purchase by FLS XI at $17.00.
-
Pre-IPO Private Placement Conversion
FLS XI's stake includes 5,565,980 shares from the conversion of preferred stock purchased in private transactions for approximately $59.98 million, plus 588,235 shares bought in the IPO.
-
180-Day Lock-Up on FLS XI Shares
A lock-up agreement prevents FLS XI from disposing of or hedging its shares for 180 days post-IPO, limiting near-term selling pressure.
Analysis · ATTO · Life Sciences
A prominent life sciences venture capital group, Frazier Life Sciences, has disclosed a combined 15.3% stake in Attovia Therapeutics following the company's recent IPO. The 13D reveals that Frazier entities purchased an additional $3.3 million worth of shares in the open market on August 5–7 at prices between $19.37 and $22.00, on top of the previously reported $10 million IPO purchase by FLS XI. With total holdings of nearly 7 million shares, including pre-IPO private placements, the group signals strong institutional conviction in Attovia's prospects—especially as the stock trades near its 52-week low. The filing also notes that FLS XI is subject to a 180-day lock-up agreement, limiting near-term selling pressure.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATTO was trading at $18.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.7M. The 52-week trading range was $18.50 to $22.79. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.